Clinical Trial: Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency

U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07385846) titled 'Pilot Study of Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma With Mismatch Repair Deficiency' on Jan. 26.

Brief Summary: Navigated Focused Ultrasound and Pembrolizumab in the Treatment of Recurrent WHO Grade 4 IDH-Wildtype Glioblastoma with Mismatch Repair Deficiency.

Study Start Date: June 01, 2026

Study Type: INTERVENTIONAL

Condition: Glioblastoma Mismatch Repair Deficiency

Intervention: DRUG: Pembrolizumab

Treatment dosing will be 200mg of pembrolizumab every three weeks for up to six months or until disease progression, whichever occurs first.

DEVICE: Na...